RT Journal Article SR Electronic T1 ANCA-associated vasculitis JF Clinical Medicine JO Clin Med FD Royal College of Physicians SP 60 OP 64 DO 10.7861/clinmedicine.17-1-60 VO 17 IS 1 A1 Max Yates A1 Richard Watts YR 2017 UL http://www.rcpjournals.org/content/17/1/60.abstract AB The vasculitides are a heterogeneous group of conditions typified by their ability to cause vessel inflammation with or without necrosis. They present with a wide variety of signs and symptoms and, if left untreated, carry a significant burden of mortality and morbidity. The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are three separate conditions – granulomatosis with polyangiitis (GPA; formerly known as Wegener’s granulomatosis), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA; previously known as Churg-Strauss syndrome). This review examines recent developments in the pathogenesis and treatment of AAV, focusing on developments in treatment following the introduction of rituximab, in particular.